Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy

Overview

Journal JCO Precis Oncol

Specialty Oncology

Date 2021 Sep 27

PMID 34568722

Citations 2

Authors

Valeria Gerthofer

Alexander Scheiter

Florian Luke

Felix Keil

Kirsten Utpatel

Laura-Maria-Giovanna Pohmerer

Johannes Seitz

Christoph Niessen

Atanas Ignatov

Wolfgang Dietmaier

Diego F Calvisi

Matthias Evert

Olaf Ortmann

Stephan Seitz

Affiliations

Soon will be listed here.

Citing Articles

Reticular Myxoid Odontogenic Neoplasm with Novel STRN::ALK Fusion: Report of 2 Cases in 3-Year-Old Males.

Rosebush M, Housley Smith M, Cordell K, Callahan N, Zaid W, Gagan J Head Neck Pathol. 2024; 18(1):26.

PMID: 38526831 PMC: 10963713. DOI: 10.1007/s12105-024-01633-6.

Clinical Next Generation Sequencing Application in Mesothelioma: Finding a Golden Needle in the Haystack.

Cerbone L, Orecchia S, Bertino P, Delfanti S, De Angelis A, Grosso F Cancers (Basel). 2023; 15(24).

PMID: 38136262 PMC: 10741845. DOI: 10.3390/cancers15245716.

Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review.

Wu X, Wang Q, Xu X Front Oncol. 2023; 13:1156329.

PMID: 37152028 PMC: 10160359. DOI: 10.3389/fonc.2023.1156329.

References

Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J . The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016; 22(22):5527-5538. DOI: 10.1158/1078-0432.CCR-16-0569. View

Rottgers S, Gombert M, Teigler-Schlegel A, Busch K, Gamerdinger U, Slany R . ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia. 2010; 24(6):1197-200. DOI: 10.1038/leu.2010.18. View

Magge D, Zenati M, Austin F, Mavanur A, Sathaiah M, Ramalingam L . Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2013; 21(4):1159-65. PMC: 4100549. DOI: 10.1245/s10434-013-3358-y. View

Peters S, Camidge D, Shaw A, Gadgeel S, Ahn J, Kim D . Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):829-838. DOI: 10.1056/NEJMoa1704795. View

Kay M, Dehghanian F . Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation. J Mol Model. 2017; 23(11):323. DOI: 10.1007/s00894-017-3495-5. View

Hofman P . Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice. Cells. 2021; 10(1). PMC: 7830674. DOI: 10.3390/cells10010168. View

Morris S, Kirstein M, Valentine M, Dittmer K, Shapiro D, Saltman D . Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994; 263(5151):1281-4. DOI: 10.1126/science.8122112. View

Coluccia A, Perego S, Cleris L, Gunby R, Passoni L, Marchesi E . Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood. 2003; 103(7):2787-94. DOI: 10.1182/blood-2003-09-3144. View

Katayama R, Shaw A, Khan T, Mino-Kenudson M, Solomon B, Halmos B . Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012; 4(120):120ra17. PMC: 3385512. DOI: 10.1126/scitranslmed.3003316. View

10.

Kelly L, Barila G, Liu P, Evdokimova V, Trivedi S, Panebianco F . Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A. 2014; 111(11):4233-8. PMC: 3964116. DOI: 10.1073/pnas.1321937111. View

11.

Murumagi A, Ungureanu D, Arjama M, Butzow R, Lohi J, Sariola H . STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells. Transl Oncol. 2021; 14(4):101027. PMC: 7851186. DOI: 10.1016/j.tranon.2021.101027. View

12.

Kusano H, Togashi Y, Akiba J, Moriya F, Baba K, Matsuzaki N . Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene. Am J Surg Pathol. 2016; 40(6):761-9. DOI: 10.1097/PAS.0000000000000610. View

13.

Camidge D, Kim H, Ahn M, Yang J, Han J, Hochmair M . Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020; 38(31):3592-3603. PMC: 7605398. DOI: 10.1200/JCO.20.00505. View

14.

Kimbara S, Takeda K, Fukushima H, Inoue T, Okada H, Shibata Y . A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib. Jpn J Clin Oncol. 2014; 44(9):868-71. DOI: 10.1093/jjco/hyu069. View

15.

Fontana D, Ceccon M, Gambacorti-Passerini C, Mologni L . Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Med. 2015; 4(7):953-65. PMC: 4529334. DOI: 10.1002/cam4.413. View

16.

Malpica A, Euscher E, Marques-Piubelli M, Ferrufino-Schmidt M, Miranda R, Sams R . Malignant Mesothelioma of the Peritoneum in Women: A Clinicopathologic Study of 164 Cases. Am J Surg Pathol. 2020; 45(1):45-58. DOI: 10.1097/PAS.0000000000001545. View

17.

Friboulet L, Li N, Katayama R, Lee C, Gainor J, Crystal A . The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014; 4(6):662-673. PMC: 4068971. DOI: 10.1158/2159-8290.CD-13-0846. View

18.

Robinson B, Lake R . Advances in malignant mesothelioma. N Engl J Med. 2005; 353(15):1591-603. DOI: 10.1056/NEJMra050152. View

19.

Dagogo-Jack I, Rooney M, Lin J, Nagy R, Yeap B, Hubbeling H . Treatment with Next-Generation ALK Inhibitors Fuels Plasma Mutation Diversity. Clin Cancer Res. 2019; 25(22):6662-6670. PMC: 6858956. DOI: 10.1158/1078-0432.CCR-19-1436. View

20.

Huang D, Kim D, Kotsakis A, Deng S, Lira P, Ho S . Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics. 2013; 102(3):157-62. DOI: 10.1016/j.ygeno.2013.02.006. View